While continuing efforts to optimize the production and treatment algorithm of CAR T-cell therapy, therapeutic agents not targeting BCMA, such as CAR/TCR-engineered T-cell therapies targeting other neoantigens and the enrichment of MILs with intrinsic anti-myeloma reactivity, are worth attention and further clinical development. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.